Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23819281 | 1.00 | HPRT1 (0.36) | HPRT1ALDH1A1RIPK1CTSGGAA | |
| SCHEMBL26292462 | 0.89 | RIPK1 (0.32) | RIPK1BTN3A1 | |
| SCHEMBL26290564 | 0.88 | RIPK1 (0.32) | RIPK1BTN3A1 | |
| SCHEMBL23818643 | 0.88 | BTN3A1 (0.41) | RIPK1BTN3A1 | |
| SCHEMBL23818622 | 0.87 | BTN3A1 (0.43) | RIPK1BTN3A1 | |
| SCHEMBL26335903 | 0.87 | BTN3A1 (0.43) | RIPK1BTN3A1 | |
| SCHEMBL26290368 | 0.86 | BTN3A1 (0.42) | RIPK1BTN3A1 | |
| SCHEMBL23818639 | 0.85 | BTN3A1 (0.37) | RIPK1BTN3A1 | |
| SCHEMBL26290847 | 0.85 | BTN3A1 (0.38) | RIPK1BTN3A1 | |
| SCHEMBL26290623 | 0.85 | RIPK1 (0.31) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | HPRT1 150/4885ALDH1A1 1459/4885RIPK1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.